NCT06686771

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression In Patients With Metastatic Non-Small-Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 320 (estimated)
• Sponsor: Canadian Cancer Trials Group · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.

Detailed description

The usual approach for patients who are not in a study and whose disease has gotten worse is to switch treatments. Sometimes, combinations of drugs or radiotherapy are used. The study doctor can explain which treatment may be best. These treatments can reduce symptoms and may stop the tumour from growing for several months or longer.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
RADIATION	SBRT	Please refer to the current NCCN NSCLC guidelines for possible treatment options
OTHER	First or second-line standard of care therapy	Please refer to the current NCCN NSCLC guidelines for possible treatment options.

Timeline

• Start date: 2025-12-16
• Primary completion: 2030-02-28
• Completion: 2030-12-31
• First posted: 2024-11-13
• Last updated: 2026-04-14

Locations

57 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated device study